The frontMIND study adds two immune‑based medicines (tafasitamab and lenalidomide) to standard R‑CHOP, a type of chemotherapy ...

Primary mediastinal B-cell lymphoma (PMBCL) is a rare and aggressive type of non-Hodgkin’s lymphoma that originates in the white blood cells behind the breastbone. Although the cause of PMBCL is ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

B-cell lymphoma may cause abdominal swelling, chest pressure, and bone weakening as lymphoma cells affect different organs. Treatments like chemotherapy and immunotherapy for B-cell lymphoma may ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 ...

Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with ...

Hodgkin lymphoma and primary mediastinal B-cell lymphoma are two aggressive blood cancers that affect young people between their late teens and mid-30s, a group often referred to as Adolescents and ...

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis." Normally, a B cell ...